GlassScriptPhysician profile
Oliver K Sevilla
NPI 1871567669
$6,378.23
in general payments reported to CMS, 2019-2025
25 companies · $4,399 in 2025
The $4,399 reported for 2025 was more than what 87% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $205 · 2020: $199 · 2021: $102 · 2022: $355 · 2023: $524 · 2024: $594 · 2025: $4,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,888 · Travel and Lodging: $1,129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,888.31 |
| Travel and Lodging | $1,128.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,660.53 | 2025 | |
| Glaxosmithkline, LLC. | $662.78 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.76 | 2019-2025 | Ofev, Spiriva Respimat |
| Genzyme Corporation | $258.74 | 2023-2025 | |
| Genentech USA, INC. | $249.16 | 2020-2022 | |
| Insmed, INC. | $147.87 | 2020-2025 | Arikayce, Brinsupri |
| Fujifilm Healthcare Americas Corporation | $145.94 | 2024 | Fujifilm |
| Pulmonx Corporation | $144.33 | 2023-2024 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Mylan Specialty L.P. | $132.15 | 2022-2024 | Yupelri |
| Grifols USA, LLC | $128.28 | 2024-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $78.53 | 2019-2025 | Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $65.56 | 2022-2024 | Xarelto |
| Inogen, INC. | $61.01 | 2022-2025 | |
| Verona Pharma, INC. | $58.06 | 2025 | Ohtuvayre |
| Jazz Pharmaceuticals INC. | $52.71 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Circulation INC | $51.64 | 2020 | |
| Viatris Specialty LLC | $47.38 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $23.93 | 2023 | Inspire |
| United Therapeutics Corporation | $23.29 | 2024 | Tyvaso |
| Takeda Pharmaceuticals U.S.A., INC. | $21.53 | 2025 | Glassia |
| Xeris Pharmaceuticals, INC. | $15.82 | 2025 | Gvoke Hypopen |
| Mallinckrodt Hospital Products INC. | $15.73 | 2023 | Acthar |
| Harmony Biosciences LLC | $15.34 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $13.09 | 2021 | |
| Tactile Systems Technology INC | $13.07 | 2023 | Flexitouch Plus, Entre Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oliver Sevilla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.